In the past week, PALI stock has gone down by -22.56%, with a monthly decline of -43.72% and a quarterly plunge of -59.41%. The volatility ratio for the week is 10.67%, and the volatility levels for the last 30 days are 10.67% for Palisade Bio Inc The simple moving average for the past 20 days is -26.18% for PALI’s stock, with a -70.58% simple moving average for the past 200 days.
Is It Worth Investing in Palisade Bio Inc (NASDAQ: PALI) Right Now?
Additionally, the 36-month beta value for PALI is 1.46. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for PALI is 2.74M and currently, short sellers hold a 5.00% ratio of that float. The average trading volume of PALI on February 13, 2025 was 1.57M shares.
PALI) stock’s latest price update
Palisade Bio Inc (NASDAQ: PALI)’s stock price has gone decline by -8.85 in comparison to its previous close of 1.13, however, the company has experienced a -22.56% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-02-10 that Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a favorable safety profile in single-ascending-dose cohorts Carlsbad, CA, Feb. 10, 2025 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the presentation of positive preclinical data from PALI-2108, an orally administered, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug is in development for patients with ulcerative colitis (UC). Palisade Bio presented a poster titled “PALI-2108, a Colon-Specific PDE4B Inhibitor Prodrug, Reduces Ulcerative Colitis Symptoms in an Acute Colitis DSS Mouse Model” at the Crohn’s & Colitis Congress in San Francisco, CA.
PALI Trading at -39.01% from the 50-Day Moving Average
After a stumble in the market that brought PALI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.33% of loss for the given period.
Volatility was left at 10.67%, however, over the last 30 days, the volatility rate increased by 10.67%, as shares sank -41.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -57.44% lower at present.
During the last 5 trading sessions, PALI fell by -22.56%, which changed the moving average for the period of 200-days by -83.47% in comparison to the 20-day moving average, which settled at $1.3952. In addition, Palisade Bio Inc saw -37.58% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PALI starting from Williams Donald Allen, who purchase 1,000 shares at the price of $4.86 back on May 28 ’24. After this action, Williams Donald Allen now owns 1,000 shares of Palisade Bio Inc, valued at $4,863 using the latest closing price.
Finley John David, the CEO, CFO, Director of Palisade Bio Inc, purchase 1,000 shares at $4.81 during a trade that took place back on May 24 ’24, which means that Finley John David is holding 8,437 shares at $4,810 based on the most recent closing price.
Stock Fundamentals for PALI
Current profitability levels for the company are sitting at:
- 59.07 for the present operating margin
- 1.22 for the gross margin
The net margin for Palisade Bio Inc stands at 56.26. The total capital return value is set at -2.22. Equity return is now at value -135.96, with -106.54 for asset returns.
Based on Palisade Bio Inc (PALI), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -35.18. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -1136.0.
Currently, EBITDA for the company is -12.28 million with net debt to EBITDA at 0.53. When we switch over and look at the enterprise to sales, we see a ratio of 19.34. The receivables turnover for the company is -2.6for trailing twelve months and the total asset turnover is -0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.28.
Conclusion
In conclusion, Palisade Bio Inc (PALI) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
